Moderna reports vaccine remains highly effective through six months

Moderna Inc. today announced during an investors report that its COVID-19 vaccine remains 93% effective through the first six months following a full dosing regimen.

Moderna also reported that, in its effort to earn full Food and Drug Administration approval for the vaccine, it initiated the rolling submission process for a Biologics License Application for the current vaccine in the U.S., a process it expects to complete its submission in August. Moderna also has completed enrollment for a phase 1 clinical trial of a next-generation COVID-19 vaccine that will be refrigerator-stable.